Side Effects of Immunotherapy in Systemic Therapy of Hepatocellular Carcinoma (HCC)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034321

Enrollment

120

Registered

2025-01-23

Start date

2024-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Patients with HCC receiving immune system therapy. This non-interventional retrospective observational study includes patients who were prescribed immune system therapy during a routine clin

Eligibility

Sex/Gender

All

Age

18 Years to 84 Years

Inclusion criteria

Inclusion criteria: - Patients with HCC and immune system therapy - Age = 18 years and < 85 years

Exclusion criteria

Exclusion criteria: - Patients with fibrolamellar HCC - Patients < 18 and = 85 years - Patients with a contraindication to immune system therapy

Design outcomes

Primary

Measure	Time frame
Frequency and Severity of Immunotherapy Side Effects in Systemic Therapy of Hepatocellular Carcinoma (HCC)	—

Secondary

Measure	Time frame
Treatment response of immunotherapy in systemic therapy of hepatocellular carcinoma (HCC): a) Overall survival b) Progression-free survival c) Response rates	—

Countries

Germany

Contacts

Public ContactNatascha Röhlen

Uniklinik Freiburg

natascha.roehlen@uniklinik-freiburg.de004976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026